4.5 Article

DEPDC5 mutations are not a frequent cause of familial temporal lobe epilepsy

Journal

EPILEPSIA
Volume 56, Issue 10, Pages E168-E171

Publisher

WILEY-BLACKWELL
DOI: 10.1111/epi.13094

Keywords

Temporal lobe seizures; Genetics; Mutation; Familial focal epilepsy with variable foci

Funding

  1. Telethon-Italy [GGP12078]
  2. Genetics Commission of the Italian League Against Epilepsy

Ask authors/readers for more resources

Mutations in the DEPDC5 (DEP domain-containing protein 5) gene are a major cause of familial focal epilepsy with variable foci (FFEVF) and are predicted to account for 12-37% of families with inherited focal epilepsies. To assess the clinical impact of DEPDC5 mutations in familial temporal lobe epilepsy, we screened a collection of Italian families with either autosomal dominant lateral temporal epilepsy (ADLTE) or familial mesial temporal lobe epilepsy (FMTLE). The probands of 28 families classified as ADLTE and 17 families as FMTLE were screened for DEPDC5 mutations by whole exome or targeted massive parallel sequencing. Putative mutations were validated by Sanger sequencing. We identified a DEPDC5 nonsense mutation (c.918C>G; p.Tyr306*) in a family with two affected members, clinically classified as FMTLE. The proband had temporal lobe seizures with prominent psychic symptoms (deja vu, derealization, and forced thoughts); her mother had temporal lobe seizures, mainly featuring visceral epigastric auras and anxiety. In total, we found a single DEPDC5 mutation in one of (2.2%) 45 families with genetic temporal lobe epilepsy, a proportion much lower than that reported in other inherited focal epilepsies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Spectrum of epilepsy with eyelid myoclonia: Delineation of disease subtypes from a large multicenter study

Emanuele Cerulli Irelli, Enrico Cocchi, Georgia Ramantani, Antonella Riva, Roberto Horacio Caraballo, Alessandra Morano, Loretta Giuliano, Tulay Yilmaz, Eleni Panagiotakaki, Francesca F. Operto, Beatriz Gonzalez Giraldez, Simona Balestrini, Katri Silvennoinen, Sara Casciato, Marion Comajuan, Francesco Fortunato, Anna Teresa Giallonardo, Rimma Gamirova, Antonietta Coppola, Giancarlo Di Gennaro, Angelo Labate, Vito Sofia, Gerhard Josef Kluger, Antonio Gambardella, Dorothee G. A. Kasteleijn-NolstTrenite, Betul Baykan, Sanjay M. Sisodiya, Alexis Arzimanoglou, Pasquale Striano, Carlo Di Bonaventura

Summary: Based on age at epilepsy onset (AEO), this study identified three subtypes of objective epilepsy with eyelid myoclonia (EEM) and analyzed their distinct clinical features. Early onset EEM was associated with higher rates of intellectual disability, antiseizure medication refractoriness, and psychiatric comorbidities, while late onset EEM had the highest proportion of myoclonia involving body regions other than eyelids and generalized tonic-clonic seizures. Intermediate onset EEM had the lowest observed rate of additional findings. Family history of EEM was more frequent in the subtypes with intermediate and late onset. Patients with body-MYO showed higher rates of migraine and generalized tonic-clonic seizures.

EPILEPSIA (2023)

Article Clinical Neurology

De novo KCNA6 variants with attenuated KV1.6 channel deactivation in patients with epilepsy

Vincenzo Salpietro, Valentina Galassi Deforie, Stephanie Efthymiou, Emer O'Connor, Anna Marce-Grau, Reza Maroofian, Pasquale Striano, Federico Zara, Michelle M. Morrow, Adi Reich, Amy Blevins, Julia Sala-Coromina, Andrea Accogli, Sara Fortuna, Marie Alesandrini, P. Y. Billie Au, Nilika Shah Singhal, Benjamin Cogne, Bertrand Isidor, Michael G. Hanna, Alfons Macaya, Dimitri M. Kullmann, Henry Houlden, Roope Mannikko

Summary: Novel mutations in KCNA6 gene were found to be associated with early infantile epileptic phenotypes and neurodevelopmental anomalies. Functional characterization revealed that these mutations affect channel closure and voltage dependence. This study is the first to report the association between de novo variants in KCNA6 and neurological features.

EPILEPSIA (2023)

Article Clinical Neurology

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic

Giuseppe Magro, Stefania Barone, Federico Tosto, Antonio De Martino, Domenico Santange Lo, Lucia Manzo, Angelo Pascarella, Pietro Bruno, Marilisa Pasquale, Antonio Gambardella, Paola Valentino

Summary: This study investigated the occurrence of wearing-off symptoms (WoS) in patients treated with Natalizumab using an extended interval dosing (ExID) compared to standard interval dosing (StID). The results showed no significant difference in the prevalence of WoS between the ExID and StID groups, but WoS was strongly correlated with higher EDSS and FSS. The safety and efficacy of Natalizumab with ExID were relatively preserved in this cohort of patients.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Perampanel as precision therapy in rare genetic epilepsies

Andreea Nissenkorn, Gerhard Kluger, Susanne Schubert-Bast, Allan Bayat, Marya Bobylova, Paolo Bonanni, Berten Ceulemans, Antonietta Coppola, Carlo Di Bonaventura, Martha Feucht, Anne Fuchs, Gudrun Groeppel, Gali Heimer, Brigitte Herdt, Sviatlana Kulikova, Konstantin Mukhin, Stefania Nicassio, Alessandro Orsini, Maria Panagiotou, Milka Pringsheim, Burkhard Puest, Olga Pylaeva, Georgia Ramantani, Maria Tsekoura, Paolo Ricciardelli, Tally Lerman Sagie, Brigit Stark, Pasquale Striano, Andreas van Baalen, Matthias De Wachter, Emanuele Cerulli Irelli, Claudia Cuccurullo, Celina von Stuelpnagel, Angelo Russo

Summary: A study involving 137 patients with different genetic epilepsies showed that perampanel had high efficacy in treating rare genetic epilepsies, especially in genes such as SCN1A, GNAO1, PIGA, PCDH19, SYNGAP1, CDKL5, NEU1, and POLG. This suggests a targeted effect of perampanel related to glutamate transmission in these patients, demonstrating good safety and efficacy.

EPILEPSIA (2023)

Correction Pharmacology & Pharmacy

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine (vol 13, 832929, 2022)

Gianluca Dini, Eleonora Tulli, Giovanni Battista Dell'Isola, Elisabetta Mencaroni, Giuseppe Di Cara, Pasquale Striano, Alberto Verrotti

FRONTIERS IN PHARMACOLOGY (2023)

Review Genetics & Heredity

Case report: LAMC3-associated cortical malformations: Case report of a novel stop-gain variant and literature review

Giovanni Falcicchio, Antonella Riva, Angela La Neve, Michele Iacomino, Patrizia Lastella, Patrizia Suppressa, Vittorio Sciruicchio, Maria Trojano, Pasquale Striano

Summary: This case report describes a male patient with malformations of cortical development, characterized by polymicrogyria in the occipital and temporal lobes bilaterally. Exome sequencing identified a novel stop-gain variant in the LAMC3 gene. This case highlights the phenotypic heterogeneity associated with genetic variants and the unexpected involvement of different brain regions.

FRONTIERS IN GENETICS (2023)

Article Clinical Neurology

KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties

Maria Cristina Cioclu, Ilaria Mosca, Paolo Ambrosino, Deborah Puzo, Allan Bayat, Saskia B. Wortmann, Johannes Koch, Vincent Strehlow, Kentaro Shirai, Naomichi Matsumoto, Stephan J. Sanders, Vincent Michaud, Marine Legendre, Antonella Riva, Pasquale Striano, Hiltrud Muhle, Manuela Pendziwiat, Gaetan Lesca, Giuseppe Donato Mangano, Rosaria Nardello, Johannes R. Lemke, Rikke S. Moller, Maria Virginia Soldovieri, Guido Rubboli, Maurizio Taglialatela

Summary: This study describes the phenotypic and genetic features of patients with KCNT2-related developmental epileptic encephalopathy (DEE), and investigates the functional and pharmacological properties of KCNT2 channels carrying novel or previously untested variants. The results expand the phenotypic and genotypic spectrum of KCNT2-related disorders, and highlight the need for targeted therapies based on the molecular phenotype.

ANNALS OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Exome sequencing data screening to identify undiagnosed Aromatic L-amino acid decarboxylase deficiency in neurodevelopmental disorders

Antonella Riva, Michele Iacomino, Chiara Piccardo, Laura Franceschetti, Rossella Franchini, Alessandra Baroni, Carlo Minetti, Giovanni Bisello, Federico Zara, Marcello Scala, Pasquale Striano, Mariarita Bertoldi

Summary: AADC deficiency is a rare genetic disorder characterized by developmental delay, hypotonia, and oculogyric crises. Through genetic screening, we identified DDC gene mutations in two patients with different clinical manifestations. This study improves the accuracy of AADC deficiency diagnosis and holds significance for patient management.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2023)

Article Genetics & Heredity

Genotype-phenotype correlation in contactin-associated protein-like 2 (CNTNAP-2) developmental disorder

Gianluca D'Onofrio, Andrea Accogli, Mariasavina Severino, Haluk Caliskan, Tomislav Kokotovic, Antonela Blazekovic, Kristina Gotovac Jercic, Silvana Markovic, Tamara Zigman, Krnjak Goran, Nina Barisic, Vlasta Duranovic, Ana Ban, Fran Borovecki, Danijela Petkovic Ramadza, Ivo Baric, Walid Fazeli, Peter Herkenrath, Carla Marini, Roberta Vittorini, Vykuntaraju Gowda, Arjan Bouman, Clarissa Rocca, Issam Azmi Alkhawaja, Bibi Nazia Murtaza, Malik Mujaddad Ur Rehman, Chadi Al Alam, Gisele Nader, Maria Margherita Mancardi, Thea Giacomini, Siddharth Srivastava, Javeria Raza Alvi, Hoda Tomoum, Sara Matricardi, Michele Iacomino, Antonella Riva, Marcello Scala, Francesca Madia, Angela Pistorio, Vincenzo Salpietro, Carlo Minetti, Jean-Baptiste Riviere, Myriam Srour, Stephanie Efthymiou, Reza Maroofian, Henry Houlden, Sonja Catherine Vernes, Federico Zara, Pasquale Striano, Vanja Nagy

Summary: The CNTNAP2 gene encodes CASPR2, a presynaptic type 1 transmembrane protein, involved in cell-cell adhesion and synaptic interactions. Biallelic CNTNAP2 loss has been associated with Pitt-Hopkins-like syndrome-1, while the pathogenic role of heterozygous variants remains controversial. In this study, 22 novel patients with CNTNAP2 variants were identified, and a genotype-phenotype correlation was characterized. The presence of biallelic variants was significantly associated with global developmental delay, epilepsy, hyporeflexia, autism spectrum disorder, language impairment, and severe cognitive impairment.

HUMAN GENETICS (2023)

Review Genetics & Heredity

The burden of illness in Lennox-Gastaut syndrome: a systematic literature review

Adam Strzelczyk, Sameer M. M. Zuberi, Pasquale Striano, Felix Rosenow, Susanne Schubert-Bast

Summary: This study conducted a systematic literature review on the burden of illness in Lennox-Gastaut syndrome (LGS), finding that LGS patients suffer from drug-resistant epilepsy and cognitive dysfunction. The research on the epidemiology, treatment costs, and patient quality of life in LGS is limited, indicating a need for further investigation.

ORPHANET JOURNAL OF RARE DISEASES (2023)

Article Genetics & Heredity

GLUT1-DS Italian registry: past, present, and future: a useful tool for rare disorders

Costanza Varesio, Valentina De Giorgis, Pierangelo Veggiotti, Nardo Nardocci, Tiziana Granata, Francesca Ragona, Ludovica Pasca, Martina Maria Mensi, Renato Borgatti, Sara Olivotto, Roberto Previtali, Antonella Riva, Maria Margherita Mancardi, Pasquale Striano, Mara Cavallin, Renzo Guerrini, Francesca Felicia Operto, Alice Pizzolato, Ruggero Di Maulo, Fabiola Martino, Andrea Lodi, Carla Marini

Summary: This study describes the implementation of a national web-based registry for GLUT1-DS, which provides real-world data on the disease. Data from 67 patients were collected, revealing that most patients experienced symptoms within the first year of life and the majority are currently undergoing Ketogenic dietary treatment.

ORPHANET JOURNAL OF RARE DISEASES (2023)

Review Clinical Neurology

Efficacy and Safety of Fenfluramine in Epilepsy: A Systematic Review and Meta-analysis

Payam Tabaee Damavandi, Natalia Fabin, Riccardo Giossi, Sara Matricardi, Cinzia Del Giovane, Pasquale Striano, Stefano Meletti, Francesco Brigo, Eugen Trinka, Simona Lattanzi

Summary: This systematic review assessed the efficacy and safety of Fenfluramine (FFA) for the treatment of seizures in patients with epilepsy. The results showed that FFA significantly reduces seizure frequency in patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), but is also associated with adverse events such as decreased appetite, diarrhea, fatigue, and weight loss.

NEUROLOGY AND THERAPY (2023)

Article Clinical Neurology

Cortico-muscular coherence and brain networks in familial adult myoclonic epilepsy and progressive myoclonic epilepsy

Silvana Franceschetti, Elisa Visani, Ferruccio Panzica, Antonietta Coppola, Pasquale Striano, Laura Canafoglia

Summary: This study aimed to identify suitable measures to explain the different severity of Familial Adult Myoclonic Epilepsy (FAME) compared to Progressive Myoclonic Epilepsy (PMEs) and detect the signature of the distinctive brain networks. The results showed that FAME2 patients had better localized CMC and increased betweenness-centrality (BC) compared to EPM1 patients, which played a role in improving and spreading myoclonus. Additionally, the brain network impairments were more severe in FAME2 patients.

CLINICAL NEUROPHYSIOLOGY (2023)

Article Clinical Neurology

Epilepsy with generalized tonic-clonic seizures alone: Electroclinical features and prognostic patterns

Emanuele Cerulli Irelli, Joanna Gesche, Sophie Schlabitz, Francesco Fortunato, Cecilia Catania, Alessandra Morano, Angelo Labate, Bernd J. Vorderwuelbecke, Antonio Gambardella, Betuel Baykan, Martin Holtkamp, Carlo Di Bonaventura, Christoph P. Beier

Summary: This multicenter retrospective study investigated the electroclinical features, seizure outcome, and antiseizure medication withdrawal in a large cohort of GTCA patients. The study found a low rate of drug resistance and a high prevalence of early response to treatment in GTCA patients.

EPILEPSIA (2023)

Article Law

Pediatric Drug Studies Might Be the Largest Abuse in Medical Research in History. It Is Time for Lawyers to Step In

Klaus Rose, Jane M. Grant-Kels, Pasquale Striano, Tanjinatus Oishi, David Neubauer, Earl B. Ettienne

Summary: A new type of research is being conducted that requests separate clinical studies for vaccines and drugs in minors under 18 years of age, in accordance with pediatric laws in the United States and European Union. However, these studies may be pointless as minors often mature before their 18th birthday and are not significantly different from adults physiologically.

JOURNAL OF LAW AND MEDICINE (2023)

No Data Available